Trending

IPF

5th Antifibrotic Drug Development Summit -AFDD-

5th Antifibrotic Drug Development Summit -AFDD-

5th Antifibrotic Drug Development Summit -AFDD-

X

5th Antifibrotic Drug Development Summit -AFDD-

https://pharmaphorum.com/events/5th-antifibrotic-drug-development-summit-afdd/

Galecto raises $64m to finance EU filing for inhaled IPF drug

Galecto raises $64m to finance EU filing for inhaled IPF drug

Privately-held biotech Galecto has raised $64m with an equity funding round to further research into treatments for drugs

X

Galecto raises $64m to finance EU filing for inhaled IPF drug

https://pharmaphorum.com/news/galecto-raises-64m-to-finance-eu-filing-for-inhaled-ipf-drug/

Redx shares soar after IPF drug licence deal with AstraZeneca

Redx shares soar after IPF drug licence deal with AstraZeneca

Shares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to

X

Redx shares soar after IPF drug licence deal with AstraZeneca

https://pharmaphorum.com/news/redx-shares-soar-after-ipf-drug-deal-with-astrazeneca/

Boehringer announces IPF deal with Korea’s Bridge Biotherapeutics

Boehringer announces IPF deal with Korea’s Bridge Biotherapeutics

Boehringer Ingelheim and South Korean biotech Bridge Biotherapeutics have announced a deal to develop the latter’s drug for

X

Boehringer announces IPF deal with Korea’s Bridge Biotherapeutics

https://pharmaphorum.com/news/boehringer-announces-ipf-deal-with-koreas-bridge-therapeutics/

Boehringer files for new rare disease use for nintedanib in EU, US

Boehringer files for new rare disease use for nintedanib in EU, US

Boehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe,

X

Boehringer files for new rare disease use for nintedanib in EU, US

https://pharmaphorum.com/news/boehringer-files-for-new-rare-disease-use-for-nintedanib-in-eu-us/

Biomarker trial to show drug value in rare lung disease

Biomarker trial to show drug value in rare lung disease

Growing incidence of IPF raises need for better means of determining diagnosis and treatment success.

X

Biomarker trial to show drug value in rare lung disease

https://pharmaphorum.com/news/biomarker-trial-show-drug-value-rare-lung-disease/

Patient perspective: living with rare lung disease IPF

Patient perspective: living with rare lung disease IPF

Idiopathic pulmonary fibrosis (IPF) is a fatal disease that’s all the more difficult for patients because of a

X

Patient perspective: living with rare lung disease IPF

https://pharmaphorum.com/views-and-analysis/patient-perspective-living-with-rare-lung-disease-ipf/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com